NASDAQ:HSIC - Henry Schein Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $62.39 +0.02 (+0.03 %) (As of 02/15/2019 04:00 PM ET)Previous Close$62.39Today's Range$62.12 - $63.1952-Week Range$57.78 - $91.35Volume2.44 million shsAverage Volume1.98 million shsMarket Capitalization$9.51 billionP/E Ratio17.33Dividend YieldN/ABeta0.89 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York. Receive HSIC News and Ratings via Email Sign-up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical & hospital equipment Sub-IndustryHealth Care Distributors SectorMedical Current SymbolNASDAQ:HSIC Previous Symbol CUSIP80640710 Webwww.henryschein.com Phone631-843-5500Debt Debt-to-Equity Ratio0.29 Current Ratio1.30 Quick Ratio0.70Price-To-Earnings Trailing P/E Ratio17.33 Forward P/E Ratio15.14 P/E Growth1.84 Sales & Book Value Annual Sales$12.46 billion Price / Sales0.76 Cash Flow$4.8857 per share Price / Cash Flow12.77 Book Value$18.00 per share Price / Book3.47Profitability EPS (Most Recent Fiscal Year)$3.60 Net Income$406.29 million Net Margins3.00% Return on Equity20.40% Return on Assets7.71%Miscellaneous Employees22,000 Outstanding Shares152,438,000Market Cap$9.51 billion OptionableOptionable Henry Schein (NASDAQ:HSIC) Frequently Asked Questions What is Henry Schein's stock symbol? Henry Schein trades on the NASDAQ under the ticker symbol "HSIC." When did Henry Schein's stock split? How did Henry Schein's stock split work? Shares of Henry Schein split on the morning of Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were distributed to shareholders after the closing bell on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split. How will Henry Schein's stock buyback program work? Henry Schein declared that its Board of Directors has approved a share buyback plan on Thursday, December 13th 2018, which permits the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.1% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's management believes its stock is undervalued. How were Henry Schein's earnings last quarter? Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings results on Monday, August, 6th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The firm had revenue of $3.33 billion for the quarter, compared to the consensus estimate of $3.31 billion. Henry Schein had a net margin of 3.00% and a return on equity of 20.40%. The company's quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $0.88 earnings per share. View Henry Schein's Earnings History. When is Henry Schein's next earnings date? Henry Schein is scheduled to release their next quarterly earnings announcement on Wednesday, February 20th 2019. View Earnings Estimates for Henry Schein. How can I listen to Henry Schein's earnings call? Henry Schein will be holding an earnings conference call on Wednesday, February 20th at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link. What price target have analysts set for HSIC? 17 Wall Street analysts have issued 12-month price objectives for Henry Schein's stock. Their forecasts range from $66.00 to $102.00. On average, they expect Henry Schein's stock price to reach $82.7327 in the next twelve months. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Henry Schein. What is the consensus analysts' recommendation for Henry Schein? 17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 4 sell ratings, 7 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Henry Schein. What are Wall Street analysts saying about Henry Schein stock? Here are some recent quotes from research analysts about Henry Schein stock: 1. According to Zacks Investment Research, "We are disappointed with the year-over-year deterioration in Henry Schein’s operating margin due to escalating expenses. We currently await the completion of the planned spin-off of the company’s global Animal Health business. The spin-off is expected to bring in major changes to Henry Schein’s overall operating results. Pricing pressure and tough competition are major woes. However, all of the company's operating segments recorded year-over-year growth in the last reported quarter. Henry Schein's strong share gains in the North American markets raise optimism. We are looking forward to Henry Schein’s new exclusive distribution agreement with Sprig Oral Health Technologies Inc. Per the agreement, Henry Schein will distribute Sprig's products to help customers place crowns. Also, the company banking on digital dentistry buoys optimism. Overall, in the past six months, Henry Schein has outperformed its industry." (2/6/2019) 2. Barrington Research analysts commented, "We are currently modeling $4.10. It is important to note that management’s adjusted EPS guidance does not include any impact from the upcoming animal health spin-off and merger, which is expected to occur around year end. In addition, the guidance does not factor in any future M&A activity." (11/8/2018) Has Henry Schein been receiving favorable news coverage? Media coverage about HSIC stock has been trending neutral on Saturday, InfoTrie reports. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Henry Schein earned a news impact score of 0.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days. Who are some of Henry Schein's key competitors? Some companies that are related to Henry Schein include Edwards Lifesciences (EW), Takeda Pharmaceutical (TKPYY), Actelion (ALIOF), FRESENIUS SE &/S (FSNUY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), ESSILOR INTL S/S (ESLOY), Centene (CNC), McKesson (MCK), Zimmer Biomet (ZBH), Fresenius Medical Care AG & Co. (FMS), Eisai (ESALY), TERUMO CORP/ADR (TRUMY), LONZA GRP AG/ADR (LZAGY) and Canopy Growth (WEED). Who are Henry Schein's key executives? Henry Schein's management team includes the folowing people: Mr. Stanley M. Bergman, Exec. Chairman & CEO (Age 69)Mr. James P. Breslawski, Vice Chairman & Pres (Age 65)Mr. Steven Paladino, Exec. VP, CFO & Exec. Director (Age 62)Mr. Gerald A. Benjamin, Exec. VP, Chief Admin. Officer & Director (Age 66)Mr. Ronald South, Chief Accounting Officer & VP of Corp. Fin. Who are Henry Schein's major shareholders? Henry Schein's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Longview Partners Guernsey LTD (8.67%), BlackRock Inc. (7.29%), Atlanta Capital Management Co. L L C (4.10%), Alecta Pensionsforsakring Omsesidigt (2.87%), Mackenzie Financial Corp (2.65%) and Geode Capital Management LLC (1.38%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Lorelei Mcglynn, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Paul Brons, Paul Rose, Philip A Laskawy, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein. Which major investors are selling Henry Schein stock? HSIC stock was sold by a variety of institutional investors in the last quarter, including Congress Asset Management Co. MA, Park West Asset Management LLC, Alecta Pensionsforsakring Omsesidigt, Mackenzie Financial Corp, Longview Partners Guernsey LTD, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Swedbank and SG Americas Securities LLC. Company insiders that have sold Henry Schein company stock in the last year include David Mckinley, Mark E Mlotek, Michael S Ettinger, Paul Brons, Stanley M Bergman and Steven Paladino. View Insider Buying and Selling for Henry Schein. Which major investors are buying Henry Schein stock? HSIC stock was acquired by a variety of institutional investors in the last quarter, including Atlanta Capital Management Co. L L C, BlackRock Inc., Retirement Systems of Alabama, State of Tennessee Treasury Department, California Public Employees Retirement System, D. E. Shaw & Co. Inc., First Trust Advisors LP and Prudential PLC. View Insider Buying and Selling for Henry Schein. How do I buy shares of Henry Schein? Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Henry Schein's stock price today? One share of HSIC stock can currently be purchased for approximately $62.39. How big of a company is Henry Schein? Henry Schein has a market capitalization of $9.51 billion and generates $12.46 billion in revenue each year. The company earns $406.29 million in net income (profit) each year or $3.60 on an earnings per share basis. Henry Schein employs 22,000 workers across the globe. What is Henry Schein's official website? The official website for Henry Schein is http://www.henryschein.com. How can I contact Henry Schein? Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at 631-843-5500 or via email at [email protected] MarketBeat Community Rating for Henry Schein (NASDAQ HSIC)Community Ranking: 1.8 out of 5 ()Outperform Votes: 266 (Vote Outperform)Underperform Votes: 472 (Vote Underperform)Total Votes: 738MarketBeat's community ratings are surveys of what our community members think about Henry Schein and other stocks. Vote "Outperform" if you believe HSIC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSIC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/16/2019 by MarketBeat.com StaffFeatured Article: How accurate is the Rule of 72?